Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers

NCT00189540 is registered in ClinicalTrials.gov with AnGes USA, Inc. as lead sponsor.

NCT NCT00189540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Limb Ischemia in Subjects Who Have Peripheral Ischemic Ulcers
Lead sponsor
AnGes USA, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
August 31, 2008
Enrollment
27 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

arterial occlusive disease, ischemia, peripheral vascular disease, ulcers